ALLO icon

Allogene Therapeutics
ALLO

Overview Fund Activity

156 hedge funds and large institutions have $208M invested in Allogene Therapeutics in 2025 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 51 increasing their positions, 46 reducing their positions, and 27 closing their positions.

Holders
156
Holders Change
-13
Holders Change %
-7.69%
% of All Funds
2.1%
Holding in Top 10
6
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.08%
New
17
Increased
51
Reduced
46
Closed
27
Calls
$139K
Puts
$75K
Net Calls
+$64K
Net Calls Change
-$228K

Top Buyers

1
Millennium Management
1
Millennium Management
New York
$1.7M
2
Royal Bank of Canada
2
Royal Bank of Canada
Ontario, Canada
$1.11M
3
Primecap Management
3
Primecap Management
California
$6.46M
4
Geode Capital Management
4
Geode Capital Management
Massachusetts
$4.29M
5
GCM
5
Graham Capital Management
Connecticut
$342K

Top Sellers

1
Fidelity Investments
1
Fidelity Investments
Massachusetts
$1.11M
2
JPMorgan Chase & Co
2
JPMorgan Chase & Co
New York
$1.06M
3
Morgan Stanley
3
Morgan Stanley
New York
$688K
4
Capital World Investors
4
Capital World Investors
California
$12.6M
5
Jane Street
5
Jane Street
New York
$466K
Name Market Value Shares Shares
Change 		Shares
Change %
P
1
Pfizer
New York
$24.9M 22,032,040 – –
TGA
2
TPG GP A
Texas
$21.1M 18,716,306 – –
BlackRock
3
BlackRock
New York
$20.2M 17,897,400 -35,506 -0.2%
Capital World Investors
4
Capital World Investors
California
$12.6M 11,150,000 -1,115,330 -9%
LCM
5
Lynx1 Capital Management
Puerto Rico
$12.5M 11,057,009 – –
DGM
6
Darwin Global Management
Jersey
$12.4M 10,479,791 +30,000 +0.3%
Citadel Advisors
7
Citadel Advisors
Florida
$11.6M 10,252,606 +49,277 +0.5%
Vanguard Group
8
Vanguard Group
Pennsylvania
$9.33M 8,259,128 +191,575 +2%
Primecap Management
9
Primecap Management
California
$6.46M 5,719,140 +787,300 +16%
Goldman Sachs
10
Goldman Sachs
New York
$6.22M 5,503,141 -350,833 -6%
WP
11
Woodline Partners
California
$4.93M 4,360,608 – –
T. Rowe Price Associates
12
T. Rowe Price Associates
Maryland
$4.56M 4,030,872 -175,132 -4%
FLSM
13
Frazier Life Sciences Management
California
$4.37M 3,868,750 – –
Geode Capital Management
14
Geode Capital Management
Massachusetts
$4.29M 3,794,827 +435,389 +13%
FCMV
15
Foresite Capital Management VI
California
$3.25M 2,875,357 -572,918 -17%
WCM
16
Wildcat Capital Management
New York
$3.12M 2,920,787 – –
Dimensional Fund Advisors
17
Dimensional Fund Advisors
Texas
$3.09M 2,736,419 -443,434 -14%
State Street
18
State Street
Massachusetts
$3.08M 2,722,742 -67,035 -2%
PSC
19
Patient Square Capital
California
$2.98M 2,635,000 +266,814 +11%
UBS Group
20
UBS Group
Switzerland
$2.3M 2,038,919 -104,191 -5%
VVA
21
Vida Ventures Advisors
Massachusetts
$2.03M 1,798,163 – –
Two Sigma Advisers
22
Two Sigma Advisers
New York
$2M 1,767,400 -433,400 -20%
Renaissance Technologies
23
Renaissance Technologies
New York
$1.89M 1,670,012 +113,312 +7%
Two Sigma Investments
24
Two Sigma Investments
New York
$1.82M 1,613,225 -461,874 -22%
Millennium Management
25
Millennium Management
New York
$1.7M 1,502,724 +1,245,875 +485%
1
2 3 4 5